IL6 and Crohn disease: Tocilizumab, a humanized monoclonal anti-IL-6R antibody that is an FDA-approved drug for rheumatic arthritis and Crohn’s disease, competitively binds to both soluble and membrane-bound IL-6 receptors and blocks the intracellular IL-6 signaling pathway [45].